# PH Share Price Performance Analysis: $253 (June 2022) → ~$800 (November 2025)

**Analysis Date:** November 2025  
**Performance Period:** June 2022 to November 2025 (~3.5 years)  
**Total Return:** ~216% gain (316% total return including dividends)  
**CAGR:** ~35% annualized return

---

## The Performance Paradox

**The Disqualification Rationale:**
- PH was disqualified because investment thesis focuses on **margin expansion rather than revenue growth**
- 1% organic revenue growth vs 24% EPS growth
- "Not aligned with growth-focused investment approach"

**The Reality:**
- Share price: **$253 → ~$800** (~216% gain, ~35% CAGR)
- This is **exceptional performance** - better than most "growth" companies

**The Question:** How did a company with 1% revenue growth generate 35% annualized returns?

---

## Deconstructing PH's Returns: The Margin Expansion + Multiple Expansion Story

### The Three Drivers of PH's Share Price Appreciation

#### 1. **EPS Growth (Margin Expansion)**
- **FY22 EPS:** ~$16.04 (estimated from financials)
- **FY25 EPS:** $27.12 (GAAP) or $27.33 (adjusted)
- **EPS Growth:** +69% over 3 years (~19% CAGR)
- **Driver:** Margin expansion from 16.1% operating margin (FY23) to 20.5% (FY25)

**Margin Expansion Details:**
- Operating margin: 16.1% → 20.5% (+440 bps)
- Adjusted segment operating margin: 21.8% → 26.1% (+430 bps)
- Net margin: 10.9% → 17.8% (+690 bps)

**Result:** EPS grew 69% despite revenue being essentially flat

#### 2. **Multiple Expansion (Valuation Re-rating)**
- **June 2022 P/E:** ~15-16x (estimated, based on $253 price and ~$16 EPS)
- **Current P/E:** 27.96x TTM
- **Multiple Expansion:** ~75-85% increase
- **Driver:** Market recognizing operational excellence and margin expansion sustainability

**Valuation Evolution:**
- Market initially valued PH as cyclical industrial company
- As margins expanded and became sustainable, market re-rated to premium industrial multiple
- Premium justified by industry-leading margins (26.1% adjusted)

**Result:** Multiple expansion contributed ~40-50% of total return

#### 3. **Share Buybacks (Per-Share Value Enhancement)**
- **FY25 Share Repurchases:** $1.76B (~7% of market cap)
- **Share Count Reduction:** ~128.6M diluted shares (FY25)
- **Per-Share Value:** Each remaining share represents larger portion of company

**Result:** Buybacks enhanced per-share metrics beyond fundamental improvement

---

## The Math: How $253 → $800

### Scenario Analysis

**Base Case (No Multiple Expansion):**
- EPS growth: $16 → $27 (+69%)
- Multiple maintained: 15.5x P/E
- **Share Price:** $27 × 15.5 = **$419** (66% gain, not enough)

**Actual Case (With Multiple Expansion):**
- EPS growth: $16 → $27 (+69%)
- Multiple expansion: 15.5x → 27.96x (+80%)
- **Share Price:** $27 × 27.96 = **$755** (198% gain, close to actual)

**Reality Check:**
- $253 → $800 = **216% gain**
- This matches EPS growth (69%) + Multiple expansion (80%) + Share buybacks enhancement

---

## Why This Worked: The Margin Expansion Story

### The Investment Thesis That Worked

**1. Operational Excellence → Margin Expansion**
- The Win Strategy™ drove continuous improvement
- Margin expansion from 16% → 26% (adjusted segment operating margin)
- This was **structural**, not cyclical

**2. Portfolio Transformation**
- Shift to longer-cycle/secular revenue mix (2/3 of portfolio)
- Aerospace growth (8%+ organic) at higher margins
- Reduced cyclicality = reduced earnings volatility

**3. Cash Generation → Share Buybacks**
- $3.8B operating cash flow (19% of sales)
- $1.76B share repurchases (FY25)
- Debt reduction ($1.35B) improving capital structure

**4. Market Recognition**
- Market initially undervalued operational improvements
- As margins proved sustainable, multiple expanded
- Premium multiple justified by industry-leading margins

---

## The Investment Case: Why PH Was Actually a Great Investment

### The "Not Growth-Focused" Argument Was Wrong (From a Returns Perspective)

**What We Said:**
- "Investment thesis focuses on margin expansion rather than revenue growth"
- "Not aligned with growth-focused investment approach"

**What Actually Happened:**
- 35% CAGR returns (exceptional)
- Better than most "growth" companies
- Margin expansion + multiple expansion = superior returns

### The Real Investment Case

**PH's Investment Thesis:**
1. **Margin Expansion:** Operational excellence driving structural margin improvement
2. **EPS Growth:** 24% annual EPS growth despite 1% revenue growth
3. **Multiple Expansion:** Market recognizing operational excellence
4. **Capital Efficiency:** Cash generation funding buybacks and debt reduction

**Result:** 35% CAGR returns

---

## Comparison: PH vs "Growth" Companies

### PH Performance (June 2022 → November 2025)
- **Total Return:** ~216% (~35% CAGR)
- **Revenue Growth:** 1% organic
- **EPS Growth:** 24% annual (margin expansion driven)
- **Multiple Expansion:** 15.5x → 27.96x (+80%)

### "Growth" Company Performance (Hypothetical)
- **Total Return:** Varies widely
- **Revenue Growth:** 10-20%+
- **EPS Growth:** 10-15% (if margins maintained)
- **Multiple:** Could expand or contract

**Key Insight:** PH's margin expansion + multiple expansion generated better returns than many "growth" companies.

---

## Why We Disqualified PH (And Why That Might Have Been Wrong)

### The Disqualification Rationale

**Our Logic:**
- User's investment thesis focuses on **revenue growth**
- PH shows 1% organic revenue growth (not growth-focused)
- Disqualified based on investment thesis alignment

**The Reality:**
- PH generated **exceptional returns** (35% CAGR)
- Margin expansion + multiple expansion = superior performance
- "Not growth-focused" ≠ "Bad investment"

### The Lesson

**Investment Thesis Types:**
1. **Growth Thesis:** Revenue growth → earnings growth → returns
2. **Margin Expansion Thesis:** Margin expansion → EPS growth → multiple expansion → returns
3. **Value Thesis:** Undervaluation → multiple expansion → returns

**PH's Thesis:** Margin expansion + multiple expansion (worked brilliantly)

**Our Mistake:** Disqualifying a company that generates exceptional returns because it doesn't fit a "growth-focused" thesis, even though it's clearly a great investment.

---

## Updated Assessment: PH Investment Case

### Why PH Was Actually a Great Investment

**1. Exceptional Returns**
- 35% CAGR (June 2022 → November 2025)
- Better than most "growth" companies
- Demonstrates effectiveness of margin expansion thesis

**2. Sustainable Margin Expansion**
- Structural improvements (not cyclical)
- The Win Strategy™ operational excellence
- Portfolio transformation supporting margins

**3. Multiple Expansion Justified**
- Market recognizing operational excellence
- Industry-leading margins (26.1% adjusted)
- Premium multiple sustainable if execution continues

**4. Capital Efficiency**
- Strong cash generation ($3.8B operating cash flow)
- Share buybacks enhancing per-share value
- Debt reduction improving capital structure

---

## The Investment Lesson

### What We Learned

**1. Multiple Ways to Generate Returns**
- Revenue growth is one path
- Margin expansion + multiple expansion is another path
- Both can generate exceptional returns

**2. Don't Disqualify Based on Single Metric**
- PH's 1% revenue growth ≠ bad investment
- 35% CAGR returns = exceptional investment
- Look at total return potential, not just revenue growth

**3. The Margin Expansion Thesis Works**
- Operational excellence → margin expansion
- Margin expansion → EPS growth
- EPS growth + multiple expansion → exceptional returns

**4. Investment Thesis Alignment ≠ Returns**
- Our investment thesis focuses on revenue growth
- PH's thesis focuses on margin expansion
- Both can generate exceptional returns
- Don't disqualify based on thesis mismatch if returns are exceptional

---

## Conclusion

**PH's Performance:**
- **$253 → $800** (~216% gain, ~35% CAGR)
- **Exceptional returns** despite 1% revenue growth
- **Margin expansion + multiple expansion** = superior performance

**Why It Worked:**
1. EPS growth: 69% over 3 years (margin expansion driven)
2. Multiple expansion: 15.5x → 27.96x (+80%)
3. Share buybacks: Enhanced per-share value

**The Lesson:**
- Don't disqualify investments based on single metrics
- Margin expansion can generate exceptional returns
- Multiple expansion justified by operational excellence
- Investment thesis alignment ≠ returns (PH worked despite thesis mismatch)

**Updated Assessment:**
- PH was actually a **great investment** despite not fitting "growth-focused" thesis
- Margin expansion + multiple expansion = exceptional returns
- The disqualification was correct from a **thesis alignment** perspective but wrong from a **returns** perspective

**For Future Reference:**
- Evaluate investments on **total return potential**, not just revenue growth
- Margin expansion + multiple expansion can generate exceptional returns
- Operational excellence → margin expansion → EPS growth → multiple expansion → exceptional returns

*Analysis based on share price performance from June 2022 to November 2025 and financial data from PH's FY22-FY25 results.*
